FDA approves VeroScience and S2 Therapeutics glycemic control

TIVERTON, R.I. The Food and Drug Administration has approved a drug that the manufacturer says improves glycemic control across a broad population of patients with Type 2 diabetes.

The agency approved Cycloset (bromocriptine), which makers VeroScience and S2 Therapeutics said would be used as a standalone treatment or together with such other drugs as sulfonylurea, Bristol-Myers Squibb’s Glucophage (metformin) with sulfonylurea and others.

“For patients newly diagnosed with Type 2 diabetes or those who cannot adequately control their blood sugar with currently available medications, Cycloset provides a completely new approach to treating diabetes,” Brigham & Women’s Hospital and lead investigator of the drug’s safety trial Michael Gaziano said in a statement. “In addition, patients with Type 2 diabetes are at high risk for cardiovascular events, so it’s important that Cycloset has been demonstrated not to increase the risk of cardiovascular events such as heart attacks and may actually have potential to lower this risk.”